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Introduction
The mitogen-activated protein kinases (MAPKs) routes are highly
conserved signaling pathways that have been implicated in multiple
cellular responses, including the control of cell proliferation,
differentiation and survival (Robinson and Cobb, 1997). The MAPK
cascades are composed of modules including three classes of
protein kinases: the MAPK itself is phosphorylated and activated
by a MAPK kinase (MAPKK), which in turn is also phosphorylated
and activated by a MAPKK kinase (MAPKKK). Several MAPK
routes have been described in mammals. The extracellular signal-
regulated kinases 1 and 2 (Erk1/2) are activated by growth factors
and environmental stresses, and participate in the transduction of
proliferative signals (Widmann et al., 1999). Two other MAPKs
subfamilies, the p38 and the Jun N-terminal kinases, are activated
by cytokines or cytotoxic drugs and have mainly been linked to the
regulation of cell survival (Nebreda and Porras, 2000; Weston and
Davis, 2002). More recently another MAPK, termed Erk5 or BMK1
(big MAP kinase 1) has also been associated to the control of
cellular proliferation in response to proliferative signals, cytokines
and cellular stresses (Kato et al., 1997; Kato et al., 1998).
Hyperactivation of the Erk5 pathway has been associated with
highly aggressive forms of breast and prostate cancers (Esparis-
Ogando et al., 2002; McCracken et al., 2008; Mehta et al., 2003;
Montero et al., 2009).
Erk5/BMK1 is a MAPK whose N-terminus kinase domain is
highly homologous to the prototypical MAPKs Erk1/2 and differs
from them in having a large, unique C-terminal half not found in
other MAPK family members (Nishimoto and Nishida, 2006).
This unique region has two proline-rich domains as well as regions
that control the nucleo-cytoplasmic trafficking of Erk5 (Borges et
al., 2007; Buschbeck and Ullrich, 2005), and shares no homology
with other proteins. In addition, this region contains a potent
transcriptional activation domain (Kasler et al., 2000). A recent
report indicated that Erk5 undergoes autophosphorylation on this
C-terminal region and this process could be important in regulating
gene expression, since it would enhance the AP-1 activity
(Morimoto et al., 2007). In addition, this C-terminal zone has been
implicated in the nucleocytoplasmic trafficking of Erk5 (Borges et
al., 2007). Thus, deletion of the C-terminal Erk5 region, beyond
amino acid 699, provokes retention of Erk5 in the nucleus, and this
confers resistance to death-receptor-induced apoptosis.
Erk5 is activated by oxidative stress, hyperosmolarity and several
growth factors including epidermal growth factor (EGF) and the
neuregulins (Esparis-Ogando et al., 2002; Kato et al., 1997). MEK5
is the upstream MAPKK that specifically phosphorylates and
activates Erk5 at the consensus phosphorylation microdomain TEY
within the Erk5 activation loop (English et al., 1995; Wang et al.,
2006). Although the Erk5 N-terminal domain is very similar to
Erk1/2, Erk5 has unique biological functions that cannot be
compensated for by Erk1/2, as demonstrated by the fact that Erk5
deficiency in mice results in lethality. Thus, both Erk5- (Regan et al.,
2002; Sohn et al., 2002; Yan et al., 2003) and MEK5- (Wang et al.,
2005) deficient animals die during embryonic development from
angiogenic failure and cardiovascular defects. However, in the adult,
Erk5 is also required for endothelial cell survival and maintenance
of blood vascular integrity (Hayashi et al., 2004; Pi et al., 2005).
It has recently been reported that Erk5 might have a role in the
regulation of cell cycle progression through the control of the G2–
M transition (Cude et al., 2007; Girio et al., 2007). Cude and
collaborators showed that when both constitutively active MEK5
(MEK5DD) and Erk5 are overexpressed, the mitotic index is
increased and this effect is mediated by the NFB downstream
signaling pathway. Girio et al. showed that Erk5 is constitutively
phosphorylated in mitosis, when compared with G1 and S phases
of the cell cycle, and showed that phosphorylated Erk5 binds to
BIM, a BCL2 mediator of cell death, suggesting involvement of
Erk5 in the survival of cells along mitotic transit.
There is also evidence linking the other MAPKs routes to the
control of mitosis. Thus, inhibition of MEK1/2 by the use of dominant
negative forms, or by drugs, has been shown to delay cell cycle
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Summary
The MAP kinase Erk5 plays important roles in cellular proliferation, and has recently been implicated in the regulation of mitosis. The
classic pathway of Erk5 activation involves dual phosphorylation at its TEY microdomain by the upstream regulating kinase MEK5.
Here we describe a second pathway that controls Erk5 phosphorylation. This pathway is activated in mitotic cells and involves kinase
activities distinct from MEK5. Studies aimed at identifying these kinases suggested that CDK1 activity is required to sustain Erk5
phosphorylation in mitosis, as treatment with RO3306, a CDK1 inhibitor, reversed mitotic phosphorylation of Erk5. Moreover, CDK1
co-precipitated with Erk5 in mitotic cells. The mitotic phosphorylation of Erk5 occurs at multiple sites located at its unique C-terminal
region, within an Erk5 subdomain that has formerly been implicated in the control of the subcellular location of Erk5. Furthermore,
molecular studies indicated that phosphorylation at these sites may participate in the control of the transit of Erk5 between the cytosol
and the nucleus, in addition to regulating its transcriptional activity. Together, our results demonstrate the existence of a second Erk5
phosphorylation pathway, that is activated in mitosis, and that may participate in the regulation of Erk5 functions.
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progression (Wright et al., 1999). The molecular mechanisms behind
such action may be various. Thus, active Erk1/2 seems to
phosphorylate the spindle checkpoint protein MPS1, and this
phosphorylation is essential for the mitotic checkpoint function
(Zhao and Chen, 2006). In addition, Erk1/2 have also been implicated
in the phosphorylation of CENP-E motor protein (Zecevic et al.,
1998), histone H3 (Dyson et al., 2005), SWI-SNIF (Sif et al., 1998)
and Plk3 (Xie et al., 2004), and may also regulate the function of
Plk1, cdc2/CDK1 (Liu et al., 2004) or Myt1 (Palmer et al., 1998).
Furthermore, an alternatively spliced form of Erk1, termed Erk1c,
has also been detected in the Golgi complex of mitotic cells and is
required for the proper segregation of this apparatus to the two
daughter cells (Shaul and Seger, 2006). In addition, the Erk1/2
pathway and the p38 route have been implicated in controlling
mitotic progression both in normal and stress conditions, modulating
CDC25B activity (Astuti et al., 2009; Cha et al., 2007).
In this report we show that Erk5 is phosphorylated in mitosis
through a novel pathway that does not involve the canonical
MEK5-dependent route. Instead, inhibitor and biochemical studies
point to a role of CDK1 in controlling Erk5 phosphorylation in
mitosis. Erk5 phosphorylation occurs at multiple sites within its C-
terminal tail. Moreover, Erk5 phosphorylation at these sites may
also participate in the control of some biological properties of
Erk5, such as its subcellular location or transcriptional activation.
We propose that Erk5 may act as an important regulator of the
proliferation of mammalian cells by nucleating signals that emanate
from growth factor receptors in interphase, but also by receiving
inputs from kinases that control mitotic progression.
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Results
It has recently been described that Erk5 from mitotic HeLa cells
was detected as a more slowly migrating band in western blots
than Erk5 from interphase cells (Girio et al., 2007; Cude et al.,
2007). To analyze whether this was a general phenomenon, different
cell lines were treated with nocodazole, and Erk5 was analyzed by
immunoprecipitation and western blotting with an antibody raised
to the C-terminus of Erk5 (Esparis-Ogando et al., 2002). The
mitotic subpopulation of the distinct cell lines expressed an Erk5
that migrated slower than Erk5 isolated from interphase cells (Fig.
1A). These results indicate that the slower migrating form of Erk5
was a widespread phenomenon in mitotic mammalian cells. The
change in the migration induced by nocodazole was a reversible
process: when cells exited mitosis, Erk5 recovered its normal
migration pattern, as demonstrated in experiments in which cells
where synchronized in M phase by nocodazole treatment, and then
released into normal medium (Fig. 1B). It was possible that the
retardation in the mobility of Erk5 from cells treated with
nocodazole was due to an action of nocodazole unrelated to its
effect on mitosis. To explore this possibility, we decided to treat
HeLa cells with different drugs that also interfere with the mitotic
transition by targeting microtubules dynamics, and that have been
used in cancer therapy. Treatment with vincristine or taxotere
induced a band shift in Erk5 analogous to that of nocodazole (Fig.
1C).
In addition, when cells were synchronized in G1–S phase by
double thymidine treatment and released into normal medium, the
slower migrating form of Erk5 was found in cells transiting through
Fig. 1. Erk5 undergoes a bandshift in
mitosis. (A)The analysis of Erk5 in a panel
of cell lines of different origin demonstrates
that Erk5 migrated slower after treatment
with 200 ng/ml nocodazole (Noc) for 14
hours. Analysis of Erk5 in the mitotic cells
was performed as described in the
Materials and Methods section. (B)HeLa
cells were blocked in G2–M by nocodazole
treatment and released in normal medium.
Cells were harvested at the indicated times
after the release (in minutes). Part of the
sample was fixed for DNA content
determination by flow cytometry (cell cycle
progression shown on the right) and the
other part lysed for protein preparation.
Erk5 was immunoprecipitated and analyzed
by western blotting. 50g of protein were
probed with different cell cycle markers
such as phospho-histone H3 or cyclin B.
-tubulin was used as a loading control.
(C)Cells treated with the indicated agents
[EGF (E), nocodazole (N), taxotere (T) or
vincristine (V)] were lysed, the
immunoprecipitates separated and the
western blots probed with the anti-Erk5
antibody. (D)An Erk5 bandshift is detected
at the beginning of mitosis and disappears
at its end. HeLa cells were synchronized at
the G1–S phase of the cell cycle by a
double thymidine block and released into
normal medium and analyzed as in B.
-tubulin was used as a loading control.
AS, asynchronous population.
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mitosis, as verified by studying their cell cycle profile by flow
cytometry and western blotting with the markers phospho-histone
H3 and cyclin B (Fig. 1D). Cyclin B is normally used as a marker
of the G2–M phases of the cell cycle, because of its cyclical
expression, accumulating in G2 and at the beginning of mitosis and
being degraded at the metaphase to anaphase transition (Norbury
and Nurse, 1992; Pines and Hunter, 1991). Histone H3 is specifically
phosphorylated during mitosis and for that reason is used as a bona-
fide mitotic marker (Goto et al., 1999; Hendzel et al., 1997; Preuss
et al., 2003). These time-course experiments indicated that Erk5
mobility shift in mitosis was maximal at a time that was coincident
with the peak of histone H3 phosphorylation.
Erk5 is phosphorylated in mitosis at sites distinct from the
TEY microdomain
We then explored the causes of the different mobility of Erk5 from
mitotic cells when compared with interphase Erk5. Analogous
changes were previously reported to be provoked by changes in
the phosphorylation of Erk5, mainly triggered by the activation by
growth factor receptors (Esparis-Ogando et al., 2002; Kato et al.,
1998). In fact, treatment with EGF caused a mobility shift analogous
to that provoked by mitotic arrest of HeLa cells (Fig. 2A). For
this reason, we first analyzed whether phosphorylation was
responsible for the change in Erk5 mobility. To this end, Erk5
immunoprecipitated from EGF- or nocodazole-treated samples was
subjected to in vitro phosphatase treatment, followed by western
blot assay. Treatment with lambda phosphatase augmented the
electrophoretic mobility of mitotic Erk5, making it indistinguishable
from interphase Erk5 from unstimulated cells. This phosphatase
treatment also caused increased mobility of Erk5 from EGF-treated
interphase HeLa cells (Fig. 2A). Together, these findings indicated
that phosphorylation of Erk5 in mitotic cells was the probable
cause of its delayed mobility. We noticed that when EGF- or
nocodazole-treated samples were carefully compared, the slower
migrating bands from both treatments seemed to be slightly
different (arrows in Fig. 2B). This suggested that possibly the two
treatments affected Erk5 phosphorylation differently. To address
this, EGF- or nocodazole-stimulated cells were lysed and the
extracts immunoprecipitated with anti-Erk5 or antibodies that
recognize Erk5 at the phosphorylation sites located in the TEY
microdomain (anti-T-PEY-P antibody). The slower migrating band
appearing after EGF treatment was recognized by the anti-T-PEY-
P antibody. However, this antibody failed to react with Erk5 from
mitotic cells (Fig. 2C), indicating that Erk5 phosphorylation in
mitosis does not occur at the consensus phosphorylation
microdomain TEY. To further verify this finding, we used a form
of Erk5 in which the TEY residues had been substituted with the
non-phosphorylatable residues, AEF (Erk5AEF) (Esparis-Ogando et
al., 2002). In HeLa cells expressing this mutant (HA-Erk5AEF),
treatment with nocodazole caused the typical mitotic bandshift of
HA-tagged Erk5 (Fig. 2D). By contrast, EGF treatment was unable
to cause phosphorylation or bandshift of HA-Erk5AEF (data not
shown) (Esparis-Ogando et al., 2002). Together, these results
indicate that the phosphorylation of Erk5 in mitosis occurs at
noncanonical sites outside the TEY microdomain.
Erk5- and MEK5-independent phosphorylation of Erk5 in
mitosis
Two kinase activities have been implicated in the direct
phosphorylation of Erk5. MEK5 is responsible for the
phosphorylation of Erk5 at the TEY microdomain (Zhou et al.,
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1995; Nishimoto and Nishida, 2006). In addition, a report indicated
that once Erk5 in phosphorylated at the T-PEY-P sites, it is then
able to autophosphorylate at residues located in its C-terminal
region (Morimoto et al., 2007). We explored the participation of
both kinases as the potential Erk5 mitotic kinase. We initially took
advantage of mouse embryonic fibroblasts (MEFs) derived from
animals deficient in MEK5. Even though MEK5-deficient animals
do not survive above mid-gestation because of cardiac defects and
angiogenic failure, MEFs derived from those animals have,
however, been isolated (Wang et al., 2005). Mek5–/– MEFs were
treated with either EGF or nocodazole, and Erk5 analyzed by
western blotting. These MEFs did not respond to EGF treatment
with a band shift as MEFs derived from their wild-type littermates,
demonstrating a role of MEK5 in Erk5 phosphorylation in response
to activation of growth factor receptors. Nevertheless, the shift in
Erk5 mobility was still detectable in both MEFs after nocodazole
Fig. 2. Erk5 is phosphorylated in mitosis through a novel, MEK5-
independent route. (A)HeLa cells were treated with nocodazole (N) or EGF
(E), and Erk5 immunoprecipitated as described. Half of the sample was then
treated with lambda phosphatase where indicated, and the western blot probed
with the anti-Erk5 antibody. (B)Different migration of Erk5 after treatment
with EGF or nocodazole. Extracts from HeLa cells treated with EGF (10 nM,
15 minutes; E) or nocodazole (200 ng/ml, 14 hours; N) were
immunoprecipitated with an anti-Erk5 antibody, and the western blot probed
with the same antibody. (C)Erk5 mitotic phosphorylation does not occur at the
TEY microdomain. Extracts from HeLa cells treated with EGF or nocodazole
were immunoprecipitated with anti-Erk5 or anti-Erk5-P antibodies, and the
western blot probed with the indicated antibodies. (D)A dominant negative
form of Erk5 (HA-Erk5AEF) in which the residues that are normally
phosphorylated (Thr218 and Tyr220) had been changed to non-
phosphorylatable ones (Ala, Phe) was transfected into HeLa cells and the
ability of the exogenous Erk5 to be phosphorylated in mitosis was assessed as
described above. (E)MEK5 is not involved in the mitotic phosphorylation of
Erk5. Wild-type or MEK5-deficient MEFs (Mek5–/–) were treated with EGF or
nocodazole. Extracts were prepared and Erk5 analyzed as above. (F)Erk5
kinase activity is not necessary for its mitotic phosphorylation. A mutant form
of Erk5 in which the lysine residues involved in its kinase activity had been
substituted by other residues (Erk5KD) was transiently transfected into HeLa
cells or Erk5–/– MEFs and its ability to be phosphorylated in mitosis
determined as described.
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
treatment, indicating that, in fact, this was a MEK5-independent
event (Fig. 2E).
To analyze whether Erk5 kinase activity was necessary in a
mitotic autophosphorylation reaction, a kinase-dead mutant of Erk5
(Erk5KD) was generated. This form, in which lysines 83 and 84
were mutated to other residues was transfected into HeLa cells.
Erk5KD still suffered the characteristic mitotic shift when treated
with nocodazole (Fig. 2F, left panel). Moreover, in Erk5-deficient
cells (Wang et al., 2006), Erk5KD also suffered mitotic
phosphorylation (Fig. 2F, right panel). Together, these data indicate
that the mitotic phosphorylation of Erk5 was independent of Erk5
kinase activity. Therefore, and based in all the previous data we
can conclude that Erk5 is phosphorylated while cells transit through
mitosis, and such phosphorylation is independent of MEK5 or
Erk5 kinase activity.
CDK1 activity sustains Erk5 phosphorylation in mitosis
One of the main kinases orchestrating mitosis is the cyclin-
dependent kinase CDK1. Thus, to further identify the moment at
which Erk5 phosphorylation occurs, as well as the possible
implication of CDK1 on Erk5 phosphorylation, we took advantage
of the drug RO-3306, a specific inhibitor of CDK1 (Vassilev et al.,
2006). Treatment of interphase HeLa cells with the inhibitor
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provoked an increase in cyclin B (Fig. 3A), in accordance to its
reported action as an inhibitor of CDK1 that would block cell
cycle progression at the end of G2, just before entering mitosis.
RO3306 completely blocked Erk5 phosphorylation suggesting
either a role of CDK1 in Erk5 phosphorylation, or that Erk5
phosphorylation required entry in mitosis (Fig. 3A). In another
type of experiment, the inhibitor was added to the cells once they
had been blocked in mitosis by nocodazole, but without eliminating
the microtubule-disrupting agent. Under these conditions, Erk5
dephosphorylation was detected as soon as 10 minutes after
inhibiting CDK1 activity (Fig. 3B). The inhibitor also rapidly
triggered a decrease in phospho-histone H3 and cyclin B levels,
indicative of forced exit from mitosis. Nevertheless, HeLa cells
had not completed cytokinesis, as verified by flow cytometry,
since they still showed a G2–M peak in that assay (Fig. 3C). The
above data indicated that CDK1 activity was necessary for Erk5
phosphorylation, and opened the possibility that CDK1 could
directly interact with Erk5. To investigate such a possibility, we
explored whether Erk5 and CDK1 interacted in mitosis. Interphase
and mitotic HeLa cells extracts were immunoprecipitated with
anti-Erk5 antibodies, and the blots probed with anti-CDK1. As
shown in Fig. 3D, CDK1 and Erk5 co-precipitated, but only from
extracts of mitotic cells. This together with the data obtained with
Fig. 3. CDK1 activity is required to sustain Erk5 phosphorylation in mitosis. (A)Cells were treated with EGF (10 minutes) or with nocodazole (14 hours; Noc)
or RO-3306 (9M; RO). Erk5 immunoprecipitation and cyclin B, phospho-histone H3 and CDK1 blots were analyzed. (B)Nocodazole-treated cells were treated
with RO-3306. At the indicated times, cells were harvested, part of the sample was fixed for cytometry and the other part lysed. 1 mg protein was
immunoprecipitated with anti-Erk5 antibodies and 50g extract analyzed for the indicated proteins. CDK1 activity inhibition was demonstrated with an anti-Ser-P-
CDK (pSer-CDK)-specific antibody (bottom panel). (C)Photomicrographs and flow cytometry analysis of the cells in B. (D)Erk5 co-immunoprecipitates in vivo
with the CDK1–cyclin B complex. Asynchronous or nocodazole-treated HeLa cells were harvested in CHAPS lysis buffer (see Materials and Methods section).
After 2 hours of immunoprecipitation either with anti-Erk5 or an unrelated antibody (HA), beads were washed, proteins separated by SDS-PAGE and membranes
probed with the indicated antibodies. (E)CDK1 does not phosphorylate Erk5 in vitro. Erk5 from interphase HeLa cells was immunoprecipitated and used as a
substrate in an in vitro kinase assay in the presence or absence of ATP and active CDK1–cyclin B complex. The appearance of the Erk5 phosphorylated band
(pERK) was assessed by western blotting with the anti-Erk5 antibody (top panel). The bandshift of mitotic Erk5 is shown as a control in the rightmost lane. A
control kinase reaction using histone H1, a known CDK1 substrate was run in parallel and phosphorylation assessed with the anti-Ser-P–CDK specific antibody
(bottom panel).
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the CDK1 inhibitor pointed to the possibility that CDK1 could
directly phosphorylate Erk5. To analyze this, in vitro kinase
experiments were performed. Active CDK1–cyclin B complexes
failed to in vitro phosphorylate Erk5, as analyzed by a mobility
shift with the anti-Erk5 antibody (Fig. 3E). However, these
complexes did induce phosphorylation of histone H1, a known
substrate of CDK1 (Santamaria et al., 2007), as measured with an
anti-Ser-P–CDK substrate antibody.
Multisite phosphorylation of Erk5 in mitosis occurs in its
C-terminus
As Erk5 was not phosphorylated at the canonical sites, our next
goal was to identify the residues in Erk5 that are phosphorylated
in mitosis. Erk5 is a molecule with an N-terminal half highly
homologous to that of Erk1/2 and that differs from those MAPKs
in having a unique, long C-terminal tail that includes different
domains (Fig. 4A) (Nishimoto and Nishida, 2006; Wang and
Tournier, 2006). Nevertheless, Erk1/2 did not change its mobility
in mitosis (Fig. 4B). This could be due to the differences in the
primary sequence of Erk5 and Erk1/2, or to the fact that
phosphorylation was occurring at the unique Erk5 C-terminus. To
study the latter possibility, we analyzed whether a truncated form
of Erk5 lacking the N-terminal half of the molecule (Erk5-tail)
behaved analogously to full length Erk5. As shown in Fig. 4C,
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treatment with nocodazole caused retardation in the migration of
the Erk5-tail mutant. To more precisely map the residues of Erk5
that are phosphorylated in mitosis, several deletion mutants lacking
different parts of the C-terminal end of the molecule were used.
The mutant form Pro1 (generated by inserting a stop codon after
amino acid 412) was constructed by deleting the entire C-terminal
tail of Erk5, and was created to correspond to analogous domains
present in Erk1/2. This Erk5 form did not change its mobility in
mitotic cells, indicating that in fact the Erk1/2-like region of Erk5
did not undergo phosphorylation during mitosis (Fig. 4D). A second
deletion mutant of Erk5, created by inserting a stop codon before
the second proline-rich region (Pro2, amino acid 570) was also
unable to undergo a mobility shift in mitotic cells. Further deletion
mutants defined the region where phosphorylation of Erk5 occurred
beyond amino acid 699, and more specifically in the C-terminal
120 amino acids (Fig. 4E).
Within this region of Erk5, Morimoto and collaborators
(Morimoto et al., 2007) had identified several residues
phosphorylated by active Erk5 after transfection of a constitutively
activated MEK5 form (MEK5DD). Even though our data excluded
MEK5 or Erk5 as the C-terminal mitotic kinases, the possibility
that those residues were the targets for such a phosphorylation, due
perhaps to a predisposition for being phosphorylated, led us to
create specific point-mutants in which those potentially
phosphorylated residues were mutated to non-phosphorylatable
ones (alanine residues). In addition, we created mutants targeting
other potentially phosphorylatable sites (Fig. 5). Initially the Thr732
and two clusters of serines (that we termed S700s and S800s) were
mutated to alanines. As deduced from the decrease in the
phosphorylation of these mutants in response to nocodazole, Thr732
and at least one of the serines of each cluster of Erk5 were
phosphorylated in mitotic cells (Fig. 5B). A more detailed analysis,
in which each of the individual serines in each cluster was changed,
allowed the identification of Ser773 and Ser706 as the residues
phosphorylated in mitosis, in addition to Thr732 (Fig. 5C and data
not shown). Another set of experiments identified Ser753 as another
amino acid phosphorylated in mitosis (Fig. 5C). These approaches
permitted the identification of four different residues in the Erk5
tail that are phosphorylated in mitosis (Fig. 5C). In agreement with
this, when double (HA-Erk5T732A-S753A or HA-Erk5T732A-S773A) and
triple (HA-Erk53XPA) mutants were generated, the mobility shift
was sequentially diminished but not completely eliminated (Fig.
5D). In fact, only when the four identified phosphorylation sites
where mutated together to alanine (HA-Erk54XPA), was the bandshift
induced by nocodazole treatment completely abolished (Fig. 5E),
indicating that those four residues are phosphorylated in mitosis.
To investigate whether those residues were, in fact,
phosphorylated in mitosis, phosphospecific antibodies against some
of them (T732-P and S753-P) were generated. Immunoprecipitation
of Erk5 from nocodazole-treated cells with the anti-T732-P–Erk5
or anti-S753-P–Erk5, followed by western blotting with anti-Erk5
antibodies resulted in the identification of a band that migrated
with the same apparent relative molecular mass as Erk5
immunoprecipitated from HeLa cells treated with nocodazole (Fig.
6A). The anti-T732-P–Erk5 failed to detect Erk5 in interphase
cells, whereas the anti-S753-P–Erk5 gave a weak signal. Analogous
results were obtained when the phosphospecific antibodies were
used in western blotting using immunoprecipitated Erk5 (Fig. 6B).
The specificity of these phosphospecific antibodies was analyzed
using single and double mutants in whom the residues of interest
had been substituted by alanines. As shown in Fig. 6C, the
Fig. 4. Erk5 is phosphorylated at its C-terminal end. (A)Schematic
representation of the different domains present in Erk5 (upper part) and of
some mutants used to map the phosphorylation sites. (B)The MAPKs Erk1/2
are not phosphorylated in mitosis. 50g of extracts from HeLa cells treated
with EGF or nocodazole were analyzed by western blot with anti-Erk1/2 or
anti-Erk1/2-P antibodies. (C)Erk5 phosphorylation in mitosis occurs at its C-
terminal half. The unique tail of Erk5 was subcloned in frame with an HA
epitope and transfected into HeLa cells. After nocodazole treatment, the
mobility of the tail was determined by immunoprecipitation with the anti-HA
antibody and western blotting. (D,E)The indicated mutants lacking different
regions of the unique tail were transfected and their response to nocodazole
treatment was analyzed.
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antibodies specifically recognized those mutant Erk5 forms that
contained the indicated amino acids, but were unable to interact
with the mutant Erk5 forms in which the residue had been
substituted for a non-phosphorylatable alanine. Further proof that
the Thr732 and Ser753 were phosphorylated in mitosis came from
phosphatase experiments (Fig. 6D). Both antibodies failed to
recognize Erk5 from samples exposed to lambda phosphatase in an
in vitro phosphatase assay. We also analyzed the kinetics of Erk5
phosphorylation at these sites as cells progress through mitosis,
using the double thymidine block and release protocol described
above. These experiments showed that Thr732 and Ser753 are
phosphorylated, coincident with the progress through mitosis, and
reach a phosphorylation peak at these residues at 10 hours after the
release (Fig. 6E). Moreover, treatment with different drugs that
provoke accumulation of cells in mitosis caused T732-P and S753-
P Erk5 phosphorylation (Fig. 6F). Mitotic phosphorylation of Erk5
at these residues was also observed in a broad panel of cell lines,
indicating that these mitotic phosphorylations are a general
phenomenon (Fig. 6G).
C-terminal phosphorylation of Erk5 regulates its
subcellular location
In search of the biological implications of the phosphorylation of
Erk5 at those residues, we noticed that they fall within a region of
Erk5 previously reported to control its subcellular location (Borges
et al., 2007). This region has been shown to participate in the exit
of Erk5 from the nucleus, as its absence provokes nuclear retention
of Erk5 (Borges et al., 2007). Therefore, the possibility that the
phosphorylation at these C-terminal residues could affect Erk5
subcellular distribution was explored in interphase cells, as the
nuclear compartment is disrupted in mitosis. For these experiments,
we used Erk5-deficient cells that were transfected with HA-tagged
wild-type as well as Erk5 mutants in which the four sites identified
in the molecular and biochemical studies were converted to Ala
(Erk54XPA) or to Glu (Erk54XPE) (Fig. 7A). The HA-Erk54XPA form
migrated faster than wild-type Erk5, whereas HA-Erk54XPE
migrated slower. Immunofluorescence with anti-HA antibodies
revealed that wild-type HA-Erk5 and HA-Erk54XPA maintained an
essentially cytoplasmic distribution, according to the distribution
most frequently described for Erk5 (Borges et al., 2007) (Fig. 7B).
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By contrast, the phosphomimetic HA-Erk54XPE had a nuclear
location, supporting the idea that the residues changed are important
for Erk5 subcellular location.
Another function attributed to the C-terminal region of Erk5 is
the regulation of transcription of several target genes (Kasler et al.,
2000). We analyzed the effect of the Erk5 mutants on the activity
of a Nur77 promoter that has been used as a readout of Erk5-
dependent transcriptional activity (Carvajal-Vergara et al., 2005).
Expression of Erk5 increased transcriptional activity of the wild-
type Nur77 reporter (Fig. 7C,D). By contrast, expression of
Erk54XPA had a very small effect on the transcriptional activity of
the reporter construct. The most prominent effect on the
transcriptional activity was observed with the phosphomimetic
Erk54XPE, which increased transcriptional activity 4-fold over that
of wild-type Erk5 (Fig. 7C). As Erk54XPE was located in the
nucleus, it is possible that such localization could be responsible
for the increased transcriptional activity, independently of its
phosphorylation at the C-terminal region. To explore this, we used
a variant form of Erk5 that has previously been shown to be
retained in the nucleus of HeLa cells (Borges et al., 2007). This
form, termed Erk5699, was created by elimination of the nuclear
exclusion region present in the C-terminus of Erk5, and is devoid
of the C-terminal phosphorylation sites of Erk5 described here.
Immunofluorescence experiments demonstrated that Erk5699 was
located in the nucleus of Erk5–/– cells, suggesting that this exclusion
mechanism of Erk5 is also conserved in MEFs (Fig. 7B, lower
panels). However, Erk5699 was unable to reproduce the increase
in transcriptional activity observed with Erk54XPE or even wild-
type Erk5 (Fig. 7D). Moreover, the luciferase activity observed
upon transfection of Erk5699 was analogous to that obtained with
the non-phosphorylatable mutant Erk54XPA (Fig. 7D). Therefore,
the mere nuclear positioning of Erk5 is insufficient to confer
increased transcriptional activity, which requires phosphorylation
of the sites present in the C-terminal region.
Discussion
The mitogen-activated protein kinase Erk5 participates in animal
development, and its deregulation has been linked to the
aggressiveness of breast and prostate cancer (McCracken et al.,
2008; Montero et al., 2009). Activation of Erk5 involves dual
Fig. 5. Identification of the residues in the Erk5 tail
phosphorylated in mitosis. (A)Schematic representation
of the residues at the C-terminal end identified to be
phosphorylated in mitosis. The identified residues are
indicated in red. (B–D)Identification of the residues in the
tail of Erk5 phosphorylated in mitosis. Different mutants in
which the indicated residues had been replaced by alanine
were transiently transfected and their response to
nocodazole determined. (E)A mutant in which the four
identified residues were replaced by alanines (HA-
Erk54XPA) was generated, transfected and its response to
nocodazole treatment analyzed.
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phosphorylation at the TEY microdomain within its activation
loop, a process catalyzed by the upstream activating kinase MEK5
(Kato et al., 1997; Lee et al., 1995; Zhou et al., 1995). This
pathway involves growth factors or other stimuli to provoke
phosphorylation-mediated activation of Erk5.
Here we describe a second pathway that controls Erk5
phosphorylation and that is active in mitotic cells. Previous reports
indicated the possibility that Erk5 could be phosphorylated in mitotic
cells, as its mobility, analyzed by SDS-PAGE and western blotting,
was analogous to that obtained by activation of growth factor
receptors (Cude et al., 2007; Girio et al., 2007). However, whether
such a mobility change was due to phosphorylation was not explored.
Our in vitro phosphatase experiments demonstrate that, in fact, the
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Erk5 mobility shift in mitosis was due to phosphorylation. However,
evidence indicated that such phosphorylation did not occur at the
classical consensus sites located at the TEY microactivation domain.
First, immunoprecipitation of mitotic cell extracts with an antibody
that recognized Erk5 phosphorylated at the TEY microdomain failed
to precipitate mitotic Erk5, whereas it readily precipitated Erk5
obtained from EGF-stimulated cells. Second, an Erk5 mutant in
which the TEY sequence was changed to AEF still underwent a
mobility shift in mitosis. This latter finding also indicated that the
phosphorylation of Erk5 in mitosis is independent of a previous
phosphorylation step occurring at these sites within the
microactivation domain, and suggested that MEK5 could not be
involved in the novel phosphorylation events occurring in mitosis.
Fig. 6. Endogenous Erk5 is
phosphorylated at T732 and S753. (A)The
purified anti-T732-P (pT732; left panel) or
anti-S753-P (pS753; right panel) antibodies
were used in immunoprecipitation assays on
HeLa cells after nocodazole treatment.
Western blots were probed with the anti-
Erk5 antibody. (B)Performance of the
different antibodies generated in western
blotting. Erk5 was immunoprecipitated with
the anti-Erk5 antibody and the western blots
were probed with the different antibodies
generated, as indicated. (C)Verification of
the specificity of the generated antibodies.
Wild-type HA-Erk5 or the different HA-
labeled mutants in which one or two of the
residues identified and recognized by the
generated antibodies had been mutated to
alanine were transiently transfected. After
nocodazole treatment, lysates were
immunoprecipitated with the anti-HA
antibody and western blots probed with the
indicated antibodies. (D)HeLa cells were
treated with nocodazole and in vitro
phosphatase assay was performed as in Fig.
2A. Western blots were probed with the
antibodies indicated on the right. (E)Erk5 is
in vivo phosphorylated at T732 and S753
when cells transit through mitosis. G1–S-
synchronized HeLa cells were released into
normal medium and harvested at the
indicated times after the release (in hours).
Part of the sample was fixed for
determination of DNA content by flow
cytometry (right panel), and the other part
lysed for protein preparation. Erk5 was
immunoprecipitated and the western blots
probed with the indicated antibodies.
(F)HeLa cells treated with nocodazole (N),
taxotere (T) or vincristine (V) were lysed
and Erk5 analyzed as described above.
(G)Erk5 is phosphorylated at T732 and
S753 in many cell lines. Erk5 was
immunoprecipitated from control or mitotic
extracts, and the WB probed with the
indicated phospho-specific antibodies.
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In fact, studies carried out in MEK5-deficient cells demonstrated
that this kinase was required for growth factor-induced Erk5
phosphorylation at the TEY microdomain, and corroborated that the
phosphorylation of Erk5 that occurs in mitosis was independent on
the activity of MEK5. This finding, besides demonstrating that
mitotic Erk5 phosphorylation was MEK5 independent, opened up
the question of which kinase(s) is (are) involved in phosphorylating
Erk5 in mitosis. So far, in addition to MEK5, Erk5 has been
demonstrated to be autophosphorylated (Morimoto et al., 2007),
raising the possibility that the phosphorylation event occurring in
mitosis could be Erk5 dependent. However, it is unlikely that Erk5
is responsible for its autophosphorylation in mitosis, since a kinase-
dead version of the molecule still undergoes mitotic phosphorylation.
The different synchronization experiments performed indicated
that Erk5 is phosphorylated at the beginning of mitosis and
dephosphorylated at its end, pointing to a mitotic kinase as the one
responsible for Erk5 phosphorylation in mitosis. One of the main
kinases orchestrating mitosis is CDK1 (Santamaria et al., 2007).
Using inhibitors of this kinase, such as RO3306, we found that
CDK1 activity is required to sustain Erk5 phosphorylation in
mitosis. Thus, even a 10-minute treatment with this inhibitor
resulted in a significant reduction of Erk5 phosphorylation. This
fact may be consistent with CDK1 acting as a direct Erk5 kinase
3153Erk5 phosphorylation in mitosis
in mitosis. Moreover, two of the four phosphorylation sites of Erk5
(S706 and T732) are followed by a proline, and are CDK1
consensus target sites. However, we cannot conclude that CDK1 is
the Erk5 mitotic kinase, or at least the unique kinase, as two out
of the four identified phosphorylation residues are not consensus
phosphorylation sites for CDK1. Furthermore, even though CDK1
co-precipitated with Erk5 in mitotic cells it was unable to efficiently
phosphorylate Erk5 in vitro. Perhaps CDK1 may need a co-factor
not present in the in vitro assay, or as happens with other mitotic
kinases such as Plk1 (Elia et al., 2003), some priming could occur
in Erk5 to be afterwards phosphorylated by CDK1. Based on these
findings, we favor the hypothesis that Erk5 may be phosphorylated
by various mitotic kinases, possibly including CDK1. This is
compatible with the fact that RO3306 inhibits phosphorylation of
Erk5 in mitosis, and can be explained by (1) a direct mechanism
in which CDK1 acts as a kinase that regulates the activity of the
other Erk5 mitotic kinases, or (2) an indirect mechanism in which
maintenance of cells in mitosis is critical for their functioning as
Erk5 mitotic kinases.
The molecular studies we performed identified S706, T732,
S753 and S773 as the mitotic Erk5 phosphorylated sites. Moreover,
phosphospecific antibodies raised to two of them (T732-P and
S753-P) demonstrated that these residues are, in fact,
Fig. 7. The phosphomimicking mutant of Erk5 is retained in the nucleus. (A)Transient reconstitution of Erk5–/– MEFs with phosphomimetic and
unphosphorylatable constructs. Erk5-deficient MEFs were transfected with empty vector, HA-Erk5, HA-Erk54XPA or HA-Erk54XPE. The Erk5 forms were
immunoprecipitated with anti-HA antibodies, and the western blot probed with the anti-Erk5 antibody. (B)Subcellular localization of the different Erk5 mutants.
Transfected Erk5–/– cells were grown on glass coverslips and the Erk5 mutants and wild type identified by immunofluorescence with the anti-HA antibody,
followed by Alexa-488-labeled anti-rabbit antibody. Scale bars: 25m. (C)Transcriptional activity of the different Erk5 mutants. The indicated plasmids were co-
transfected into Erk5-deficient MEFs together with a Renilla reporter, and their transcriptional levels measured as described in the Materials and Methods section.
A representative experiment is shown; values are means of triplicate transfections with their standard deviations. (D)Erk5 nuclear location itself does not induce its
transcriptional activation.
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phosphorylated during mitosis, as indicated in the double thymidine
block–release experiments. The phosphorylated residues of Erk5
fall within a relatively short C-terminal region. We have previously
reported that deletion of this region (Erk5699) prevented nuclear
exclusion of Erk5 (Borges et al., 2007). We therefore postulated
that the phosphorylations at the mitotic sites could control the
subcellular location of Erk5. In fact, substitution of the four residues
with glutamic acid residues, in an attempt to mimic the charge
modifications occurring upon phosphorylation, resulted in an Erk5
mutant that was retained in the nucleus of interphase cells. This is
important, as some of the biological actions of Erk5, such as its
transcriptional activity or the conferring of resistance to cell death,
are expected to depend on its nuclear residency (Borges et al.,
2007; Kasler et al., 2000). In fact, when the transcriptional activity
of different mutants was analyzed, the mutant mimicking
phosphorylated Erk5, that was nuclear, showed higher
transcriptional activation properties than wild type Erk5. However,
experiments using Erk5699, which is nuclear but does not include
the phosphorylatable C-terminal sites, indicated that Erk5 merely
being resident in the nucleus cannot explain its action on
transcription. Therefore phosphorylation of these sites in interphase
cells could represent a mechanism that controls the
nucleocytoplasmic trafficking of Erk5 as well as its transcriptional
activity. Interestingly, Morimoto and collaborators identified several
residues in the Erk5 tail that are autophosphorylated in response to
the activation of the canonical MEK5-dependent pathway
(Morimoto et al., 2007) and some of them are coincident with
those that we report here. This is important as it indicates that
phosphorylation of Erk5 at its C-terminus may be involved in
signaling through the canonical MEK5-dependent pathway, as well
as in the novel MEK5-independent pathway described here.
In addition to the above mentioned studies that are required to
gain further insights into the role of Erk5 in mitosis, our work
opens several avenues of research in the Erk5 field. One important
question that needs to be studied refers to the degree of crosstalk
between the canonical and the non-canonical Erk5 phosphorylation
pathways. Whether the novel C-terminal phosphorylations may
also be triggered under other circumstances that activate the
canonical MEK5-mediated pathway, such as growth factor receptor
activation or stress conditions, must be analyzed. In fact, some
preliminary data show that activation of the canonical pathway is
able to induce Erk5 phosphorylation at least at some of the residues
identified as being important in mitosis. In addition, future
identification of the mechanisms involved in the phosphorylation
of the C-terminal residues may allow identification of the kinase(s)
responsible for Erk5 phosphorylation at these sites both in mitosis,
and also in interphase cells. From the clinical point of view, and
given the link found between Erk5 expression and patient prognosis
in cancer, it will be interesting to evaluate to what degree
phosphorylation of the Erk5 C-terminal residues is associated with
clinical parameters such as overall survival, or disease progression.
Also, as phosphorylation of these residues was found to occur in
cells treated with agents used in the oncology clinic, analysis of
Erk5 phosphorylation at these residues could serve as a biomarker
to assess the action of those or other novel antitumoral compounds.
Studies on some of these aspects are already underway.
Materials and Methods
Reagents and immunochemicals
Cell culture media, sera and G418 were purchased from Invitrogen, protein-A–
Sepharose from GE Healthcare and Immobilon P membranes from Millipore Corp.
Nocodazole, thymidine, taxotere and vincristine were from Sigma Chemical Co,
EGF was from Prospec, histone H1 from Merck, active CDK1-cyclin B complex
from New England Biolabs and RO-3306 from Calbiochem. Other generic chemicals
were purchased from Sigma Chemical Co., Roche Biochemicals or Merck.
The anti-hemagglutinin (HA) monoclonal antibody was from Roche. The
polyclonal anti-HA, anti-Erk5 (C-terminal) and anti-phospho-Erk5 (TEY) have
previously been described (Esparis-Ogando, 2002). The anti-Erk1/2, anti-phospho-
Erk1/2, anti-CDK1 and anti-cyclin B were from Santa Cruz Biotechnology, the anti-
-tubulin from Sigma, the anti-phospho-histone H3 was from Millipore and the
anti-S-P–CDK specific from Cell Signaling.
Cell culture and transfections
Human cancer cell lines were derived from a cervix adenocarcinoma (HeLa), from
human breast adenocarcinomas (MCF7, MDA-MB231 and SKBR3), ductal breast
carcinomas (BT474, T47D), head and neck cancers (KB, SCC38, SCC40, and
SCC42B) or pancreatic cancer (NP9). Erk5–/– and Mek5–/– cells are immortalized
MEFs that were generated in the laboratory of Dr. C. Tournier (Wang et al., 2006;
Wang et al., 2005). Cells were cultured at 37°C in a humidified atmosphere in the
presence of 5% CO2, 95% air. Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing high glucose and antibiotics, and supplemented with
5% (HeLa cells) or 10% (all the others) fetal bovine serum. Mouse embryonic
fibroblasts (MEFs) or HeLa cells were transfected with JetPEITM reagent (Polyplus-
transfection Inc.) following the manufacturer’s instructions. Clones were obtained
after selection with the appropriate antibiotics or transiently transfected cells were
used to perform experiments two days after the transfection.
Cell cycle synchronization and DNA analysis by flow cytometry
Cells were arrested at the different phases of the cell cycle. For G2–M
synchronization, cells were treated with 200 ng/ml nocodazole for 16 hours, and the
mitotic population was obtained by shaking them off the Petri dish. In order to
synchronize cells in G1–S, a double thymidine block was performed with sequential
exposure to 2 mM thymidine, twice for 14 hours each and with an intermediate
release of 10 hours in normal medium. After a second release and at the indicated
times, samples were harvested and an aliquot was fixed and processed for flow
cytometry. The rest of the sample was lysed for protein extraction and measurement.
For DNA analysis by flow cytometry, ethanol-fixed cells were stained with 5 g/ml
propidium iodide (PI; Sigma) and 250 g DNAse-free RNAse (Roche). A total of
30,000 cells were acquired in the PI gate using a FACSCalibur flow cytometer and
CELLQUEST software (Becton Dickinson) and analyzed on MODFIT LTTM software
(Verity software).
Protein extraction, quantification, immunoprecipitation and western
blotting
Cells were washed with phosphatase-buffered saline (PBS) and lysed as described
elsewhere (Esparis-Ogando et al., 2002). Protein content was determined by Bradford
assay and the immunoprecipitation and western blotting performed with the indicated
antibodies as described previously (Esparis-Ogando et al., 2002). For protein co-
immunoprecipitation experiments, a milder buffer was used (Vander Haar et al.,
2007). This buffer contained 40 mM HEPES at pH 7.4, 120 mM NaCl, 1 mM EDTA,
1 mM PMSF, 50 mM NaF, 1.5 mM Na3VO4, 10 mM -glycerophosphate, 0.3%
CHAPS and EDTA-free protease inhibitors (Roche). After a 2-hour
immunoprecipitation with the desired antibodies, beads were washed and separated
by SDS-PAGE, and the membranes blotted as usual.
Antibody generation
Anti–Erk5-P-specific antibodies were generated in rabbits injected with the sequences
NH2-CPPVFSGT-PPKGSGA-COOH (anti-T732-P) or NH2-CEFLNQS-PFDMGV-
COOH (anti-S753-P) corresponding to the indicated residues in the C-terminal tail of
Erk5. The keyhole limpet hemocyanin-coupled peptides were injected into rabbits
that were bled after the second boost. The antibodies from the sera were affinity
purified as described elsewhere (Esparis-Ogando et al., 2002). Fractions with an A280
greater than 0.8 were pooled and characterized by IP and western blotting as shown
in Fig. 6.
In vitro phosphatase and kinase assays
Erk5 was immunoprecipitated from cell lysates and the pellets washed as usual.
Phosphatase treatment was carried out in 70 l of phosphatase buffer containing 400
units of purified lambda phosphatase (New England Biolabs) for 2 hours at 30°C.
Erk5 was resolved in SDS-PAGE gels and western blotting performed as described.
For the in vitro kinase assay, immunoprecipitates were washed in kinase buffer
(New England Biolabs) and afterwards placed in a final volume of 30 l of the same
buffer supplemented or not with 100 M ATP and 4 units of the active complex
CKD1–cyclin B (New England Biolabs). An additional source of active CDK1–
cyclin B was from mitotic HeLa cells in which the complex was immunoprecipitated
with anti-cyclin B antibodies. The reaction was carried out at 30°C for 2 hours and
afterwards western blotting was performed to detect the slowly migrating band. In
parallel, another assay was performed on purified histone H1 (a known substrate of
CDK1) and the western blot probed with the anti-Ser-P–CDK-specific antibody as
a positive control of the reaction.
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Mutant generation
Mutagenesis of Erk5 was performed using the QuikChange site-directed mutagenesis
kit (Stratagene) on an Erk5 version tagged with an HA epitope at its N-terminal end
that has been shown to be fully functional (Esparis-Ogando et al., 2002). The
indicated amino acids were changed as follows: Erk5T732A (Thr732 to Ala), Erk5S753A
(Ser753 to Ala), Erk5S773A (Ser773 to Ala), Erk5S706A (Ser706 to Ala), Erk5S800sA
(Ser769, 771, 753 and 775 to Ala), Erk5S700sA (Ser701, 702, 704 and 706 to Ala),
Erk5T732A-S753A (Thr732 and Ser753 to Ala), Erk5T732A-S773A (Thr732 and Ser773 to
Ala), Erk53XPA (Thr732, Ser753 and Ser773 to Ala), Erk54XPA (Thr732, Ser706,
Ser753 and Ser773 to Ala), Erk54XPE (Thr732, Ser706, Ser753 and Ser773 to Glu),
Erk5KD (Lys83 and 84 to Ser and Leu, respectively). In addition, a construct
containing only the unique tail of Erk5 was generated by PCR amplification. Erk5
tail was subcloned into the pCDNA3 vector in frame with an HA epitope using
conventional molecular biology techniques. The deletion mutants as well as the
Erk5AEF mutant have previously been described (Borges et al., 2007; Esparis-Ogando
et al., 2002).
Immunofluorescence
Cells cultured on glass coverslips were fixed in 2% p-formaldehyde for 30 minutes
and permeabilized in PBS supplemented with 0.1% Triton X-100 that was afterwards
quenched in 50 mM NH4Cl. After blocking in PBS supplemented with 0.2% BSA,
cells were incubated with the anti-HA antibody (Roche) for 2 hours at room
temperature. After three washes of 5 minutes each, monolayers were incubated with
Alexa-488-conjugated secondary antibody for 30 minutes, washed and counterstained
with DAPI. Once mounted, samples were analyzed by confocal immunofluorescence
microscopy using a SP5 Leica apparatus with the LAS-AF software.
Reporter gene analysis
Empty pCDNA3, pCDNA3-HAErk5, pCDNA3-HAErk54XPA, pCDNA3-
HAErk54XPE, or pCDNA3-HAErk5699 plasmids were co-transfected into Erk5-
deficient MEFs together with plasmids encoding a luciferase gene driven by the
wild-type Nur77 promoter or a Nur77 promoter with a mutated MEF2 binding site,
which have been described previously (Woronicz et al., 1995). As a control for the
transfection efficiency, a pRLSV40 Renilla vector was also co-transfected. The final
molar ratio for the different vectors was 22:8:1 (pCDNA construct:Luciferase:Renilla).
24 hours after transfections, cells were harvested with Passive Lysis Buffer (Promega).
The Dual Luciferase System (Promega) was used according to the manufacturer’s
protocol. Readings were taken in triplicates in a Synergy4 multi-mode microplate
reader (Biotek), using the Gen5 1.05 software. Experiments were repeated at least
twice, and results show as the mean ± s.d. of triplicates from a representative
experiment.
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